COMMUNIQUÉS West-GlobeNewswire
-
Evaluate Releases Annual World Preview Report Revealing Updated Market Forecasts for the Pharmaceutical Industry
23/06/2026 -
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
23/06/2026 -
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026 -
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026 -
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026 -
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026 -
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026 -
Fieldstone Bio, TerraCore, and MIT Awarded U.S. Department of Energy Contract to Accelerate Critical Mineral Discovery
23/06/2026 -
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
23/06/2026 -
ECM Therapeutics Receives FDA 510(k) Clearance for ECMT-100 WMD
23/06/2026 -
Integra LifeSciences Announces Key Executive Appointments
23/06/2026 -
SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside
23/06/2026 -
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026 -
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
23/06/2026 -
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026 -
Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug Design
23/06/2026 -
UREVO Mid-Year Sale Brings 2026's Biggest Deal Yet to Amazon and Official Website
23/06/2026 -
Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
23/06/2026 -
Plus Therapeutics to Provide Business Update Call on June 30, 2026
23/06/2026
Pages